Newswire (Published: Thursday, February 18, 2021, Received: Thursday, February 18, 2021, 6:35:05 PM CST)
Word Count: 562
2021 FEB 18 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Researchers detail new data in Oncology - Prostate Cancer. According to news originating from Baltimore, Maryland, by NewsRx correspondents, research stated, “The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection.”
Funders for this research include Patrick C. Walsh Prostate Cancer Research Fund, Prostate Cancer Foundation, National Institutes of Health (NIH) - USA, NIH National Cancer Institute (NCI), Breast Cancer Research Foundation.
Our news journalists obtained a quote from the research from the Johns Hopkins University School of Medicine, “We assessed HRD score (defined as the sum of loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions) in three cohorts of primary prostate cancer, including a Johns Hopkins University (JHU) cohort with germline mutations in BRCA2, ATM, or CHEK2 (n = 64), the TCGA cohort (n = 391), and the PROGENE cohort (n = 102). In the JHU cohort, tumors with germline BRCA2 mutations had higher HRD scores (median = 27) than those with germline ATM or CHEK2 mutations (median = 16.5 [p = 0.029] and 9 [p < 0.001], respectively). For TCGA tumors without underlying HR pathway mutations, the median HRD score was 11, significantly lower than ovarian carcinoma lacking BRCA1/2 mutations (median = 28). In the absence of HR gene mutations, the median HRD score was unexpectedly higher among prostate cancers with TP53 mutations versus those without (17 vs. 11; p = 0.015); this finding was confirmed in the PROGENE cohort (24 vs. 16; p = 0.001). Finally, among eight BRCA2-altered patients who received olaparib, progression-free survival trended longer in those with HRD scores above versus below the median (14.9 vs. 9.9 months).”
According to the news editors, the research concluded: “HRD scores are low in primary prostate cancer and higher in cases with germline BRCA2 or somatic TP53 mutations. Germline BRCA2-altered cases have significantly higher HRD scores than germline ATM-altered or CHEK2-altered cases, consistent with the lower efficacy of PARP inhibitors among the latter.”
This research has been peer-reviewed.
For more information on this research see: Homologous Recombination Deficiency (Hrd) Score In Germline Brca2- Versus Atm-altered Prostate Cancer. Modern Pathology, 2021. Modern Pathology can be contacted at: Springernature, Campus, 4 Crinan St, London, N1 9XW, England. (Nature Publishing Group - http://www.nature.com/; Modern Pathology - http://www.nature.com/modpathol/)
The news correspondents report that additional information may be obtained from Tamara L. Lotan, Johns Hopkins University School of Medicine, Dept. of Pathology, Baltimore, MD 21205, United States. Additional authors for this research include Harsimar B. Kaur, Daniela C. Salles, Sanjana Murali, Andrea L. Richardson, Emmanuel S. Antonarakis, William B. Isaacs, Edward M. Schaeffer, Jerry S. Lanchbury, Kirsten M. Timms, Robert Brown, Olivier Cussenot and Geraldine Cancel-Tassin.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/s41379-020-00731-4. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
National Institutes of Health
The Breast Cancer Research Foundation Inc
Johns Hopkins University School of Medicine
Johns Hopkins University
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Women's Health Issues
Politics and Government
Government Agencies (U.S.)
Department of Health and Human Services
National Institutes of Health